Sorafenib News and Research

RSS

Sorafenib (Nexavar) is an oral multikinase inhibitor for the treatment of two common types of cancer, hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC).

Experimental drug better for repeat kidney cancer patients than FDA-approved equivalent

Kidney cancer patients who had already tried two or three different treatments had improved chances of preventing cancer progression with an experimental drug called tivozanib compared to an alternative approved by the U.S. Food and Drug Administration, according to a City of Hope-led study.

4 Dec 2019

Combination therapy improves survival in patients with hepatocellular carcinoma

Combination therapy with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab significantly improves overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma compared to standard of care, showed results from a phase 3 study reported at the ESMO Asia 2019 Congress.

22 Nov 2019

Study confirms effectiveness of a combination therapy for advanced liver cancer

Liver cancer affects hundreds of thousands of people annually, and there are few viable therapies for the advanced stages of its most common form--hepatocellular carcinoma.

6 Sep 2019

Repurposing drugs to outsmart cancers

In an article published today by SAGE Publishing, investigators from The Nagourney Cancer Institute and The Albert Einstein Israelite Hospital in São Paulo, Brazil, announced a new approach to identifying effective treatments for patients with advanced metastatic cancers. A drug commonly used to treat kidney and liver cancer was discovered effective for breast cancer, which may open new drug therapies to patients regardless of tumor type.

22 Mar 2019

Platinum nanoparticles show selective toxicity against liver cancer cells

In recent years, the number of targeted cancer drugs has continued to rise. However, conventional chemotherapeutic agents still play an important role in cancer treatment.

15 Feb 2019

Physicians more likely to prescribe drugs of manufacturers who paid them money

In a study published in The Oncologist, physicians treating certain cancers who consistently received payments from a cancer drug's manufacturer were more likely to prescribe that drug over alternative treatments.

6 Feb 2019

FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma

EUSA Pharma welcomes the news that FOTIVDA (tivozanib) is expected to be included in the upcoming European Society of Medical Oncology clinical practice guidelines for advanced renal cell carcinoma, anticipated to be published at the end of this year.

22 Oct 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Exelixis, Inc. today announced results from two analyses evaluating the effect of PD-L1 expression or prior treatment with immune checkpoint inhibitors on the efficacy of cabozantinib in patients with advanced renal cell carcinoma (RCC). The findings are being presented this week at the European Society for Medical Oncology 2018 Congress being held October 19-23 in Munich, Germany.

22 Oct 2018

New nanoplatform technology may reverse drug-resistance in renal cell carcinoma

A research team led by Arun Iyer, Ph.D., assistant professor of pharmaceutical sciences in the Eugene Applebaum College of Pharmacy and Health Sciences at Wayne State University, has developed a nanoplatform technology that works in combination with existing chemotherapeutic drugs that may reverse drug-resistance in renal cell carcinoma.

24 Sep 2018

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced that the China National Medical Products Administration approved the kinase inhibitor LENVIMA (lenvatinib) as a single agent for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

24 Sep 2018

CHMP provides positive opinion to Cabometyx for previously-treated patients with hepatocellular carcinoma

Ipsen announced today that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, provided a positive opinion for Cabometyx (cabozantinib) as a monotherapy for the treatment of hepatocellular carcinoma in adults who have been previously treated with sorafenib.

21 Sep 2018

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Exelixis, Inc. today announced that the National Comprehensive Cancer Network updated its Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets.

7 Sep 2018

Eisai: EC approves marketing of LENVIMA as first-line treatment for hepatocellular carcinoma

Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced today that the European Commission has granted a marketing authorization for the oral receptor tyrosine kinase inhibitor LENVIMA (lenvatinib mesylate) as a single agent for the first-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy.

23 Aug 2018

Scientists develop novel peptide drug that could potentially stop development of liver cancer

A research team led by scientists from the Cancer Institute of Singapore at the National University of Singapore has developed a novel peptide drug called FFW that could potentially stop the development of hepatocellular carcinoma or primary liver cancer.

2 Aug 2018

U.S. researchers recommend development of anti-cancer drugs based on mechanism of Namodenoson

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that U.S. researchers published scientific findings recommending development of anti-Liver Cancer Drugs based on a mechanism of action utilized by Namodenoson.

2 Jul 2018

Can-Fite provides update on Phase II clinical trial with drug candidate Namodenoson

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today provided an update on its Phase II clinical trial with drug candidate Namodenoson in the treatment of advanced hepatocellular carcinoma in patients whose disease has progressed on sorafenib therapy.

19 Jun 2018

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Bristol-Myers Squibb Company today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the Immuno-Oncology combination Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period.

1 Jun 2018

Study confirms no survival benefit of adding SIRT to standard treatment for liver cancer

The final results of the palliative cohort of the SORAMIC study in patients with unresectable, locally advanced primary liver cancer have confirmed no clinical advantage to adding selective internal radiation therapy to standard sorafenib treatment compared with using sorafenib alone.

13 Apr 2018

Scientists find new way to kill liver cancer cells

Scientists at the University of Delaware and the University of Illinois at Chicago have found a new way to kill liver cancer cells and inhibit tumor growth. First, they silence a key cellular enzyme, and then they add a powerful drug.

7 Feb 2018

Sorafenib News and Research

Experimental drug better for repeat kidney cancer patients than FDA-approved equivalent

Combination therapy improves survival in patients with hepatocellular carcinoma

Study confirms effectiveness of a combination therapy for advanced liver cancer

Repurposing drugs to outsmart cancers

Platinum nanoparticles show selective toxicity against liver cancer cells

Physicians more likely to prescribe drugs of manufacturers who paid them money

FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

New nanoplatform technology may reverse drug-resistance in renal cell carcinoma

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

CHMP provides positive opinion to Cabometyx for previously-treated patients with hepatocellular carcinoma

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Eisai: EC approves marketing of LENVIMA as first-line treatment for hepatocellular carcinoma

Scientists develop novel peptide drug that could potentially stop development of liver cancer

U.S. researchers recommend development of anti-cancer drugs based on mechanism of Namodenoson

Can-Fite provides update on Phase II clinical trial with drug candidate Namodenoson

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Study confirms no survival benefit of adding SIRT to standard treatment for liver cancer

Scientists find new way to kill liver cancer cells

Streamlining Immuno-Oncological Therapeutic Antibody Discovery

Applying a Proteomics-based Approach to the Clinic

Proteomics & DIA Mass Spectroscopy in Neurodegenerative Disease Research

Latest News